Sentence examples for loi associated with from inspiring English sources

Loss of imprinting (LOI) associated with hypomethylation at the promoter proximal sequence (DMR0) of the IGF2 gene was proposed as a predisposing constitutive risk biomarker for colorectal cancer.

LOI associated with IGF2 DMR0 hypomethylation was reported in peripheral blood at a significantly higher frequency in patients with a history of colorectal cancer than patients without (14, 15).

Loss of imprinting (LOI) is associated with colorectal neoplasia.

Perturbation of these marks leads to loss of imprinting (LOI), which is associated with developmental disorders and malignancy and may also obstruct applications of human pluripotent stem cells (hPSCs).

So while all cases with LOI had hypomethylation at IGF2 DMR0, the inverse is not true and DMR0 hypomethylation is not invariably associated with LOI in tumours.

Although it has widely been assumed that cancers with LOI will have the same methylation epigenotypes as BWS, we have previously shown that the methylation patterns associated with constitutive LOI at the IGF2 and H19 genes in BWS patients are not identical to the tumour-associated LOI in Wilms patients (36).

Furthermore, LOI of specific genes in this region has been associated with different cancers; LOI of H19 (which encodes a long non-coding RNA) is associated with lung cancer [ 52] and hepatoblastoma [ 53], and LOI of IGF2 (which encodes insulin-like growth factor 2) and H19 is associated with cervical cancer [ 54].

Loss of imprinting (LOI) in chromosome 11p15 is associated with several cancers, including Wilms tumor [ 51].

However, these changes are not associated with DLK1 LOI highlighting differences in the imprinting control mechanisms operating in the IGF2-H19 anDLK1-GTL2L2 domains.

Loss of methylation at the IGF2 DMR0 has been reported to be associated with IGF2 LOI in cancer studies including Wilms tumour (36, 37), esophageal cancer (38) and colorectal cancer (15).

Loi, S. et al. RAS/MAPK activation is associated with reduced tumor-infiltrating lymphocytes in triple-negative breast cancer: therapeutic cooperation between MEK and PD-1/PD-L1 immune checkpoint inhibitors.